AstraZeneca | pharmaphorum

Skip to main content

Thursday 25 December 2025

BlueSky linkedin youtube

header links

Get Newsletters
Media Kit

Pharmaphorum menu first category

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
Spotlight on
Events

close

SECTION

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
White Papers
Events

Channels

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

SUB NAVIGATION

Live Coverage
Partner Content
About us
Work for us
Contribute
Contact us
Advertise

Newsletters and Deep Dive digital magazine

youtube linkedin BlueSky

AstraZeneca

News

lillyhq

Lilly to research real world diabetes with digital health fi...

Eli Lilly and digital health firm Livongo are to collaborate on real-world studies and develop new insights into diabetes.

News

Diabetes finger prick

Merck/Pfizer undercut rivals with newly approved diabetes dr...

Steglatro cheaper than SGLT2 rivals from AZ and Lilly/Boehringer

News

gskhouse2

GSK's Nucala gains US use in rare autoimmune disease

IL-5 drug approved in EGPA

News

Roche Rituxan approval

Roche seizes chance for Tecentriq combo in first-line lung c...

Roche chasing lucrative label extension.

News

clovis-oncology

Clovis PARP drug gets fast US review in new ovarian cancer u...

Impressed by survival data, FDA hastens review in expanded patient group

Partner Content

600 x200 real

Partner Content

Exscientia to discuss role of AI in small molecule drug disc...

AI in small molecule drug discovery

Load more results

Editor's Picks

US BIOSECURE Act passed by Congress

Lilly points to long-lasting weight loss with orforglipron

As year-end nears, pharma groups plump up their pipelines

CDC signs off on advice ending universal hepatitis B jabs

Enhertu moves into frontline breast cancer treatment

News

CMS aims for broader GLP-1 access via federal programmes

CMS aims for broader GLP-1 access via federal programmes

CMS has revealed a new, voluntary access programme that aims to broaden the use of GLP-1 agonist medicines for diabetes and obesity.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Sales & Marketing

Physicians walking and using tablet devices

Sponsored

How to meet your physicians where they are online

A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.

Pharmaphorum Menu

Digital
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Market Access
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Oncology
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Patients
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
R&D
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Sales & Marketing
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Spotlight on

Sign up for email newsletters and Deep Dive

Get Newsletters

youtube linkedin BlueSky

About us Advertising Contact us

Contribute Cookie Policy Privacy Policy

Terms & Conditions Work for us

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2025, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2025, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company